SCHEMBL22042902

SCHEMBL22042902

O=c1[nH]c(Cl)cc2c1cnn2C1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PDE9A O76083 14/20 0.52
PDE4D Q08499 1/20 0.50
PDE1C Q14123 6/20 0.48
PDE1A P54750 4/20 0.48
PDE1B Q01064 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23905832 0.90 PDE9A (0.52) PDE9APDE4DPDE1CPDE1APDE1B
SCHEMBL23905861 0.86 PDE9A (0.58) PDE9APDE4DPDE1CPDE1B
SCHEMBL22042914 0.84 PDE9A (0.47) PDE9APDE4DPDE1B
SCHEMBL19434476 0.84 PDE9A (0.52) PDE9APDE4DPDE1CPDE1APDE1B
SCHEMBL22042906 0.82 PDE9A (0.50) PDE9A
SCHEMBL17603784 0.80 PDE9A (0.61) PDE9APDE1C
SCHEMBL30853311 0.77 PDE9A (0.47) PDE9APDE4DPDE1CPDE1APDE1B
SCHEMBL14771558 0.73 PDE9A (0.66) PDE9APDE1C
SCHEMBL7888140 0.71 PDE9A (0.74) PDE9APDE1C
SCHEMBL12079224 0.71 PDE9A (0.57) PDE9APDE4DPDE1CPDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187729-B2 Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-01-07 US disclosed
EP-3892622-B1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF KOREA RES INST CHEMICAL TECH (KR) 2024-07-24 EP disclosed
CN-113166159-B Compounds having PDE9A inhibiting activity and pharmaceutical uses thereof 韩国化学研究院 2023-10-24 CN disclosed
US-20220017528-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-01-20 US disclosed
EP-3892622-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF Korea Research Institute of Chemical Technology (KR) 2021-10-13 EP disclosed
CN-113166159-A Compound with PDE9A inhibitory activity and pharmaceutical use thereof 韩国化学研究院 2021-07-23 CN disclosed
WO-2020116972-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF 한국화학연구원 2020-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187729-B2 Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof PDE9A, PDE5A, PDE3A PDE9A 1/4885PDE4D 14/4885PDE1C 28/4885
US-20220017528-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF PDE9A, PDE5A, PDE3A PDE9A 1/4885PDE4D 14/4885PDE1C 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.